Category Archives: MS Treatment

News Release Wednesday, August 5, 2020 Collaborative network to enlist medical imaging and clinical data sciences to reveal unique features of COVID-19. The National Institutes of Health has launched the Medical Imaging and Data Resource Center (MIDRC), an ambitious effort that will harness the power of artificial intelligence and medical imaging to fight COVID-19. The multi-institutional collaboration, led by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of NIH, will create new tools that physicians can use for early detection and personalized therapies for COVID-19 patients. Continue reading →

Injections of a natural energy molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows. The study results revolve around the long-established idea that machines within animal and human cells turn the sugars, fats, and proteins we eat into energy used by the bodys millions of cells. Continue reading →

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). Continue reading →

The digital press release with multimedia content can be accessed here: Basel, August 5, 2020 Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab (OMB157) 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis (RMS). Both studies met the primary endpoints where ofatumumab showed a significant reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR)1. ASCLEPIOS I and II demonstrate the efficacy and safety of ofatumumab and its potential to become a first-choice treatment option that offers RMS patients the flexibility as they continue to live their lives, said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis Continue reading →

WASHINGTON--(BUSINESS WIRE)-- Nationally recognized neurologist Dr. Majid Fotuhi, MD, PhD, recently published an encouraging study in the Journal of Rehabilitation about a multi-disciplinary program for treating patients with Post-Concussion Syndrome a condition in which patients experience persistent concussion symptoms such as headache, memory loss, anxiety, insomnia, or brain fog for months to years after the initial injury. The statistical analysis of Fotuhis 12-week Concussion Recovery Program showed that 64% of patients who scored in the abnormal neurocognitive range before treatment experienced clinically significant improvements in their brain performance. Continue reading →

As a result of the pandemic and reduced access to face-to-face appointments, there has been a significant drop in the number of face to face assessments being carried out, and in the delivery of hands-on rehabilitation, leading many patients to be treated remotely. Continue reading →

Image source: The Motley Fool. TG Therapeutics Inc(NASDAQ:TGTX) Q22020 Earnings Call Aug 10, 2020, 8:30 a.m. ET Operator Hello, and welcome to the TG Therapeutics Second Quarter 2020 Earnings Conference Call. Continue reading →

Couples in two thirds of NHS regions are being denied IVF treatment if one of them has a child from a previous relationship, according to a new report. Continue reading →

While the Research to Accelerate Cures and Equity (RACE) Acta measure designed to promote pediatric cancer research and development of therapieswas enacted three years ago, it takes effect August 18. Continue reading →

Written by Eleanor Bird, M.S. on August 9, 2020 Fact checked by Mary Cooke, Ph.D. A new study reveals how neurons in the gut wall relay sensory information to the spinal cord and brain, which may influence mood and well-being. Continue reading →